These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 11870528

  • 1. Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PET.
    Bokemeyer C, Kollmannsberger C, Oechsle K, Dohmen BM, Pfannenberg A, Claussen CD, Bares R, Kanz L.
    Br J Cancer; 2002 Feb 12; 86(4):506-11. PubMed ID: 11870528
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Prognostic Role of Early Interim Fluorodeoxyglucose Positron Emission Tomography in Patients With Advanced Seminoma Undergoing Standard Treatment.
    Raggi D, Bandini M, Giannatempo P, Farè E, Marandino L, Colecchia M, Calareso G, Padovano B, Serafini G, Alessi A, Necchi A.
    Clin Genitourin Cancer; 2021 Jun 12; 19(3):237-245.e2. PubMed ID: 32980271
    [Abstract] [Full Text] [Related]

  • 4. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma.
    Kollmannsberger C, Oechsle K, Dohmen BM, Pfannenberg A, Bares R, Claussen CD, Kanz L, Bokemeyer C.
    Cancer; 2002 May 01; 94(9):2353-62. PubMed ID: 12015760
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study Group.
    Huddart RA, O'Doherty MJ, Padhani A, Rustin GJ, Mead GM, Joffe JK, Vasey P, Harland SJ, Logue J, Daugaard G, Hain SF, Kirk SJ, MacKewn JE, Stenning SP, NCRI Testis Tumour Clinical Study Group.
    J Clin Oncol; 2007 Jul 20; 25(21):3090-5. PubMed ID: 17634488
    [Abstract] [Full Text] [Related]

  • 16. The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours.
    Spermon JR, De Geus-Oei LF, Kiemeney LA, Witjes JA, Oyen WJ.
    BJU Int; 2002 Apr 20; 89(6):549-56. PubMed ID: 11942962
    [Abstract] [Full Text] [Related]

  • 17. Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses.
    Dennis K, Hay JH, Wilson DC.
    Clin Oncol (R Coll Radiol); 2012 Dec 20; 24(10):e168-72. PubMed ID: 22944464
    [Abstract] [Full Text] [Related]

  • 18. Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours.
    Lassen U, Daugaard G, Eigtved A, Højgaard L, Damgaard K, Rørth M.
    Eur J Nucl Med Mol Imaging; 2003 Mar 20; 30(3):396-402. PubMed ID: 12634968
    [Abstract] [Full Text] [Related]

  • 19. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
    Kumar R, Xiu Y, Potenta S, Mavi A, Zhuang H, Yu JQ, Dhurairaj T, Dadparvar S, Alavi A.
    J Nucl Med; 2004 Nov 20; 45(11):1796-803. PubMed ID: 15534046
    [Abstract] [Full Text] [Related]

  • 20. FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals.
    Becherer A, De Santis M, Karanikas G, Szabó M, Bokemeyer C, Dohmen BM, Pont J, Dudczak R, Dittrich C, Kletter K.
    Eur J Radiol; 2005 May 20; 54(2):284-8. PubMed ID: 15837411
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.